The biotechnology revolution offers unprecedented opportunities for identification of mechanistically-based biomarkers that report and predict cancer and other pathologies. The combination of genomic technologies with a knowledge of gene sequence and sequence conservation has made available markers that facilitate the correlation of genetic variation with biological outcomes, and “-omic” technologies allow efficient biochemical characterization of functional pathways—providing new markers of the susceptibility of individuals to cancer development, and of tumor susceptibility to specific therapies. New therapeutic agents targeted to individuals with specific genetic or biochemical characteristics already exist. The powerful -omic technologies allow efficient monitoring of gene transcripts, proteins, and intermediary metabolites, making it possible to monitor a large number of key cellular pathways simultaneously. This has enabled the identification of key biomarkers and signaling molecules associated with cell growth, cell death, and cellular metabolism. These new markers are facilitating monitoring of functional disturbance, molecular and cellular damage, and damage-response. Improved imaging technologies have made it feasible to image some of these molecular events noninvasively. To meet the challenge of evaluating and developing consensus criteria for the application of these new technologies and biomarkers, consortium approaches are being increasingly undertaken to share resources and to build a common understanding among the research, industry, and regulatory communities. These developments promise more efficient pharmaceutical product development, safer and more efficacious drugs, and provide clinical practitioners with new and better biomarkers for cancer screening, patient monitoring, and choice of therapy.
Aardema, M.J., and MacGregor, J.T. (2002). Toxicology and genetic toxicology in the new era of toxicogenomics: impact of “-omics” technologies. Mutat Res499, 13—25.
2.
Albertini, R.J. (2001). HPRT mutations in humans: biomarkers for mechanistic studies. Mutat Res489, 1—16.
3.
Artemov, D., Mori, N., Ravi, R., and Bhujwalla, Z.M. (2003). Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res63, 2723—27.
4.
Biomarkers Definitions Working Group. (2001 ). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Therapeutics69, 89—95.
5.
Blankenberg, F.G., Katsikis, P.D., Tait, J.F., Davis, R.E., Naumovski, L., Obtsuki, K., Kopiwoda, S., Abrams, M.J., and Strauss, H.E. (1999). Imaging of apoptosis (programmed cell death) with 99mTc annexinV. J Nucl Med40, 184—91.
6.
Cantor, C.R. (1999). Pharmacogenetics becomes pharmacogenomics: wake up and get ready. Molec Diag4, 287—8.
7.
Cantor, C.R. (2000). Biotechnology in the 21st century. Trends Biotechnol18, 6—7.
8.
Castera, L., Hartmann, D.J., Chapel, F., Guettier, C., Mall, F., Lons, T., Richardet, J.P., Grimbert, S., Morassi, O., Beaugrand, M., and Trinchet, J.C. (2000). Serum laminin and type VI collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis . J Hepatol32, 412—8.
9.
Cattley, R.C., and Radinsky, R.R. (2004). Cancer therapeutics: understanding the mechanism of action. Toxicol Pathol32, this issue.
10.
Chandler, M., and Spain, M. (2003). Pitfalls to using small animals in preclinical testing are being eliminated. Preclinica1, 245.
Davidson, J.F., Guo, H.H., and Loeb, L.A. (2002). Endogenous mutagenesis and cancer. Mutat Res509, 17—21.
13.
DeGeorge, J. (1998). Carcinogenicity testing: a new approach. In Proceeding of the 4th International Conference on Harmonization , Brussels, 1977 ( P. F. D'Arcy and D. W. G. Harron, eds.), pp. 261—3, Greystone Books, Antrim, N. Ireland.
14.
De La Vega, F.M., Dailey, D., Ziegle, J., Williams, J., Madden, D., and Gilbert, D.A. (2002). A new generation of pharmacogenomictools: a SNP linkage disequilibrium map, validated SNP assay resource, and high-throughput instrumentation for large-scale genetic studies. Biotechniques (June Suppl.), 48—50.
15.
Dobrovolsky, V.N., Casciano, D.A., and Heflich, R.H. (1999). Tk+/- mouse model for detecting in vivo mutation in an endogenous, autosomal gene. Mutat Res423, 125—36.
16.
Galloway, S.M. (1994). Chromosome aberrations induced in vitro: mechanisms, delayed expression, and intriguing questions. Environ Molec Mutagen23(Suppl. 24), 44—53.
17.
Gambhir, S.S., Barrio, J.R., Herschman, H.R., and Phelps, M.E. (1999). Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol26, 481—90.
18.
George, D.K., Ramm, G.A., Walker, N.I., Powell, L.W., and Crawford, D.H. (1999). Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in hemochromatosis. J Hepatol31, 47—52.
19.
Han, W.K., Bailly, V., Abichandani, R., Thadhani, R., and Bonventre, J.V. (2002). Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int62, 237—44.
20.
Heddle, J.A., Dean, S., Nohmi, T., Boerrigter, M., Casciano, D., Douglas, G.R., Glickman, B., Gorelick, N., Mirsalis, J., Martus, H.-J., Skopek, T., Thybaud, V., Tindall, K., and Yajima, N. (2000). In vivo transgenic mutation assays (Report of the Second International Workshop on Genotoxicity Testing, Washington, D.C., 1999). Environ Molec Mutagen35, 253—9.
21.
Hilliard, C.A., Armstrong, M.J., Bradt, C.I., Hill, R.B., Greenwood, S.K., and Galloway, S.M. (1998). Chromosome aberrations in vitro related to cytotoxicity of nonmutagenic chemicals and metabolic poisons. Environ Molec Muatagen31, 316—26.
22.
Holden, A.L. (2002). The SNP consortium: summary of a private consortium effort to develop an applied map of the human genome. Biotechniques (June Suppl.) 22—4, 26.
23.
Kilty, C., Doyle, S., Hassett, B., and Manning, F. (1998). Glutathione S-transferases as biomarkers of organ damage: Applications of rodent and canine GST enzyme immunoassays. Chem Biol Interact111—112, 123—35.
24.
Kirkland, D.J., and Müller, L. (2000). Interpretation of the biological relevance of genotoxicity test results: The importance of thresholds. Mutat Res464, 137—47.
25.
Lindon, J.C., Nicholson, J.K., Holmes, E., Antti, H., Bollard, M.E., Keun, H., Beckonert, O., Ebbels, T.M., Reily, M.D., Robertson, D., Stevens, G.J., Luke, P., Breau, A.P., Cantor, G.H., Bible, R.H., Neiderhauser, U., Senn, H., Schlotterbeck, G., Sidelmann, U.G., Laursen, S.M., Tymiak, A., Car, B.D., Lehman-McKeeman, L., Colet, J.-M., Loukaci, A., and Thomas, C. (2003). The role of metabonomics in toxicology and its evaluation by the COMET consortium. Toxicol Appl Pharmacol187, 137—46.
26.
MacDonald, J., French, J.E., Gerson, R.J., Goodman, J., Inoue, T., Jacobs, A., Kasper, P., Keller, D., Lavin, A., Long, G., McCullough, B., Sistare, F.D., Storer, R., van der Laan, J.W. (2004). The utility of genetically-modified mouse assays for identifying human carcinogens—a basic understanding and path forward . Toxicol Sci77, 188—194.
27.
MacGregor, J.T. (2003). The future of regulatory toxicology: impact of the biotechnology revolution. Toxicol Sci75, 236—48.
28.
MacGregor, J.T., Casciano, D.A., and Müller, L. (2000). Strategies and testing methods for identifying mutagenic risks. Mutat Res455, 3—21.
29.
MacGregor, J.T., Farr, S., Tucker, J.D., Heddle, J.A., Tice, R.R., and Turteltaub, K.W. (1995). New molecular endpoints and methods for routine toxicity testing. Fund Appl Toxicol26, 156—173.
30.
Maisel, A.S., Krishnaswamy, P., Nowak, R.M., McCord, J., Hollander, J.E., Duc, P., Omland, T., Storrow, A.B., Abraham, W.T., Wu, A.H.B., Clopton, P., Steg, P.G., Westheim, A., Knudsen, C.W., Perez, A., Kazanegra, R., Herrmann, H.C., and McCullough, P.A. (2002). Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New Eng J Med347, 161—67.
31.
McKinzie, P.B., Delongchamp, R.R., Heflich, R.H., and Parsons, B.L. (2001). Prospects for applying genotypic selection of somatic oncomutation to chemical risk assessment. Mutation Res489, 47—78.
32.
Mirsalis, J.C., Montforte, J.A., and Winegar, R.A. (1995). Transgenic animal models for detection of in vivo mutations. Ann Rev Pharmacol Toxicol35, 145—64.
33.
Mirsalis, J.C., Provost, G.S., Matthews, C.D., Hamner, R.T., Schindler-Horvat, J.E., O'Loughlin, K.G., MacGregor, J.T., and Short, J.M. (1993). Induction of hepatic mutations in lacI transgenic mice. Mutagenesis8, 265—71.
34.
Müller, L., and Kasper, P. (2000). Human biological relevance and the use of threshold arguments in regulatory genotoxicity assessment: experience with pharmaceuticals . Mutat Res464, 19—34.
35.
Nohmi, T., Katoh, M., Suzuki, H., Matsui, M., Yamada, M., Watanabe, M., Suzuki, M., Horiya, N., Ueda, O., Shibuya, T., Ikeda, H., and Sofuni, T. (1996). A new transgenic mouse mutagenesis test system using Spi- and 6-thioguanine selections. Environ Molec Mutagen28, 465—70.
36.
Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon, R.O. 3rd, Criqui, M., Fadl, Y.Y., Fortmann, S.P., Hong, Y., Meyers, G.L., Rifai, N., Smith, S.C. Jr., Taubert, K., Tracy, R.P., Vinicor, F., Centers for Disease Control and Prevention, American Heart Association (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation107, 499—511.
37.
Petricoin, E.F., Ardekani, A.M., Hitt, B.A., Levine, P.J., Fusaro, V.A., Steinberg, S.M., Mills, G.B., Simone, C., Fishman, D.A., Kohn, E.C., and Liotta, L.A. (2002). Use of proteomic patterns in serum to identify ovarian cancer. Lancet359, 572—7.
38.
Physician's Desk Reference. (2003). Gleevec, 2278—2282; Herceptin, 1399— 1402; Prolastin, 923—925; Antihemophilic factor, 914—919; Thomson PDR, Montvale, New Jersey.
39.
Radman, M., Jeggo, P., and Wagner, R. (1982). Chromosomal rearrangement and carcinogenesis. Mutat Res98, 249—264.
40.
Ridker, P.M., Rifai, N., Rose, L., Buring, J.E., and Cook, N.R. (2002). Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events . New Eng J Med347, 1557—65.
41.
Robinson, D.E., and MacDonald, J.S. (2001). Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute. Toxicol Pathol29 (Suppl.), 13—19.
42.
Robinson, D.E., Pettit, S.D., and Morgan, D.G. (2003). Use of genomics in mechanism based risk assessment . In Toxicogenomics (T. Inoue and W. D. Pennie, eds.), pp. 194—203. Springer-Verlag, Tokyo.
43.
Roses, A.D. (2001). 2025: the practice of neurology—back from the future. Arch Neurol58, 1766—7.
44.
Roses, A.D. (2002). Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev Drug Discov1, 541—9.
45.
Rosty, C., Christa, L., Kuzdzal, S., Baldwin, W.M., Zahurak, M.L., Carnot, F., Chan, D.W., Canto, M., Lillemore, K.D., Cameron, J.L., Yeo, C.J., Hruban, R.H., and Goggins, M. (2002). Identification ofhepatocarcinomaintestine-pancreas/pancreatitis-associatedprotein-Ias abiomarkerforpancreatic ductal adenocarcinoma by protein biochip technology . Cancer Res62, 1868—75.
46.
Shields, A.F., Mankoff, D.A., Link, J.M., Graham, M.M., Eary, J.F., Kozawa, S.M., Zheng, M., Lewellen, B., Lewellen, T.K., Grierson, J.R., and Krohn, K.A. (1998). Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med39, 1757—1762.
47.
Stambrook, P.J., Shao, C., Stockelman, M., Bovin, G., Engel, S.J., and Tishfield, J.A. (1996). APRT: a versatile in vivo resident reporter of local mutation and loss of heterozygosity. Environ Molec Mutagen28, 471—82.
48.
Stumpf, M.P. (2002). Haplotype diversity and the block structure of linkage disequilibrium. Trends Genet18, 226—8.
49.
Thybaud, V., Dean, S., Nohmi, T., de Boer, J., Douglas, G.R., Glickman, B.W., Gorelick, N.J., Heddle, J.A., Heflich, R.H., Lambert, I., Martus, H.J., Mirsalis, J.C., Suzuki, T., and Yajima, N. (2003). In vivo transgenic mutation assays (Report of the Third International Workshop on Genotoxicity Testing, Plymouth, U.K., June 28-29, 2002). Mutat Res540, 141—51.
50.
Van de Vijer, M.J., He, Y.D., van't Veer, L.J., Dai, H., Hart, A.A.M., Voskuil, D.W., Schreiber, G.J., Peterse, J.L., Roberts, C., Marton, M.J., Parrish, M., Atsma, D., Witteveen, A., Glas, A., Delahaye, L., van der Velde, T., Bartelink, H., Rodenhuis, S., Rutgers, E.T., Friend, S.H., and Bernards, R. (2002). A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med347, 1999—2009.
51.
Vasella, D., and Slater, R. (2003). Magic Cancer Bullet: How a Tiny Orange Pill is Rewriting Medical History. HarperCollins Publishers, New York.
52.
Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, H.O., Yandell, M., Evans, C.A., Holt, R.A., et al. (2001). The sequence of the human genome. Science291, 1304—51.
53.
Wallace, K.B., Hausner, E., Herman, E., Holt, G.D., MacGregor, J.T., Metz, A.L., Murphy, E., Rosenblum, I.Y., Sistare, F.D., and York, M.J.(in press). Serum troponins as biomarkers of drug-induced cardiac toxicity . Toxicol Pathol32, 106—121.
54.
Weber, W.A., Schwaiger, M., and Avril, N. (2000). Quantitative assessment of tumor metabolism using FDG-PET imaging. J Nucl Med27, 683— 687.
55.
Wijhoven, S.W., van Sloun, P.P., Kool, H.J., Weeda, G., Slater, R., Lohman, P.H., van Zeeland, A.A., and Vrieling, H. (1998). Carcinogen-induced loss of heterozygosity at the Aprt locus of somatic cells in the mouse. Proc Natl Acad Sci USA95, 13759—64.
56.
Wooster, R., and Webster, B.L. (2003). Breast and ovarian cancer. N Engl J Med348, 2339—47.
57.
Yang, B. (2003). Magic cancer bullet. Discov Med3, 16—19.
